文献速递神经MRPET

分子影像在多发性硬化管理中的机遇:从探针到治疗

Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment.
PubMed 文献 · Radiology · 2022-04-26

综述指出结构MRI(血脑屏障破坏、炎症脱髓鞘、脑与脊髓萎缩)是近40年多发性硬化疗效评价的主要指标,靶向分子探针可将评估拓展至分子层面;多数探针为PET小分子,近半源自FDA批准药物或临床试验药物。转位蛋白PET和1H磁共振波谱分别在9项和6项疾病修正治疗试验中补充分子信息,但分子影像在临床前与临床应用中仍较稀少。

要点

  • 结构MRI征象仍是多发性硬化疗效评价的主要指标。
  • 多数分子探针为PET小分子,近半源自已批准或试验中药物。
  • 转位蛋白PET与1H磁共振波谱可补充钆增强结构MRI信息。

核心结论

  • 分子影像探针可评估多发性硬化靶点位置并阐明疾病修正治疗机制,但其在临床前和临床环境中的使用仍较稀少。

研究设计与样本

  • 综述;未报告系统检索范围与纳入文献数量。
  • 总结结构MRI(钆增强)及分子影像探针在多发性硬化管理中的应用。

关键影像表现/征象

  • 结构MRI可见血脑屏障破坏、炎症与脱髓鞘、脑和脊髓萎缩等征象。
  • 超顺磁性和氟化颗粒可用于追踪循环免疫细胞(原位标记)及免疫抑制或髓鞘再生治疗干细胞(离体标记)。
  • 循环免疫细胞与治疗干细胞的追踪在临床采用质子(1H)MRI,临床前采用氟19(19F)MRI。

诊断标准与关键数值

  • 转位蛋白PET在9项多发性硬化疾病修正治疗试验中显示可补充结构(钆增强)MRI的影像指标。
  • 1H磁共振波谱在6项多发性硬化疾病修正治疗试验中显示可补充结构(钆增强)MRI的影像指标。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文指出分子影像探针在多发性硬化的临床前和临床环境中使用仍较稀少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Imaging has been a critical component of multiple sclerosis (MS) management for nearly 40 years. The visual information derived from structural MRI, that is, signs of blood-brain barrier disruption, inflammation and demyelination, and brain and spinal cord atrophy, are the primary metrics used to evaluate therapeutic efficacy in MS. The development of targeted imaging probes has expanded our ability to evaluate and monitor MS and its therapies at the molecular level. Most molecular imaging probes evaluated for MS applications are small molecules initially developed for PET, nearly half of which are derived from U.S. Food and Drug Administration-approved drugs and those currently undergoing clinical trials. Superparamagnetic and fluorinated particles have been used for tracking circulating immune cells (in situ labeling) and immunosuppressive or remyelinating therapeutic stem cells (ex vivo labeling) clinically using proton (hydrogen 1 [1H]) and preclinically using fluorine 19 (19F) MRI. Translocator protein PET and 1H MR spectroscopy have been demonstrated to complement imaging metrics from structural (gadolinium-enhanced) MRI in nine and six trials for MS disease-modifying therapies, respectively. Still, despite multiple demonstrations of the utility of molecular imaging probes to evaluate the target location and to elucidate the mechanisms of disease-modifying therapies for MS applications, their use has been sparse in both preclinical and clinical settings.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Thomas AM, Barkhof F, Bulte JWM, et al. Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment. Radiology. 2022. PMID: 35471110. doi:10.1148/radiol.211252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。